


**Product Name** : Sirpiglenastat  
**Cat. No.** : PC-38422  
**CAS No.** : 2079939-05-0  
**Molecular Formula** : C<sub>22</sub>H<sub>27</sub>N<sub>5</sub>O<sub>5</sub>  
**Molecular Weight** : 441.488  
**Target** : Other Targets  
**Solubility** : 10 mM in DMSO



## Biological Activity

DRP-104 (Sirpiglenastat) is a novel broad acting **glutamine antagonist**, has significant anticancer activity by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response.

DRP-104 (Sirpiglenastat) has significant single agent activity in various tumor types, including KEAP1 and STK11 mutant non-small cell lung cancers (NSCLC), osimertinib resistant NSCLC as well as PIK3CA/PTEN mutant head and neck squamous cell carcinoma (SCCHN).

DRP-104 mediated tumor growth inhibition (TGI) is associated with increased tumor-infiltrating leukocytes (TIL) including T, NKT, and NK cells; M1-polarized tumor associated macrophages; and decreased immune-suppressive cells such as MDSCs.

## References

Yumi Yokoyama, et al. *Cancer Res* (2021) 81 (13\_Supplement): 1563.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com